Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.83 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.55 |
| ▸ | TPH1 | P17752 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL27748337 | 1.00 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL1456075 | 1.00 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL21596546 | 1.00 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL8981412 | 1.00 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL9542800 | 1.00 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL12471720 | 1.00 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL12471725 | 1.00 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL3496039 | 0.95 | SLC7A5 (0.75) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL5027400 | 0.94 | SLC7A5 (0.73) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL3796383 | 0.94 | SLC7A5 (0.73) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148040-A1 | METHODS OF REDUCING EXERCISE-INDUCED INJURY OR ENHANCING MUSCLE RECOVERY AFTER EXERCISE | TARGET CAPITAL 4 LLC | 2024-05-09 | — | — | US | claimed |
| EP-4157358-A1 | COMPOSITIONS AND METHODS FOR TREATING FRONTOTEMPORAL DEMENTIA | biOasis Technologies Inc. (CA) | 2023-04-05 | — | — | EP | claimed |
| EP-4132563-A1 | COMPOSITIONS AND METHODS FOR TREATING LEWY BODY DEMENTIA | biOasis Technologies Inc. (CA) | 2023-02-15 | — | — | EP | claimed |
| WO-2022115353-A1 | METHODS OF REDUCING EXERCISE-INDUCED INJURY OR ENHANCING MUSCLE RECOVERY AFTER EXERCISE | INTRINSIC MEDICINE, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| WO-2021255524-A1 | COMPOSITIONS AND METHODS FOR TREATING FRONTOTEMPORAL DEMENTIA | BIOASIS TECHNOLOGIES, INC. (CA) | 2021-12-23 | — | — | WO | claimed |
| WO-2021236526-A1 | COMPOSITIONS AND METHODS FOR TREATING LEWY BODY DEMENTIA | BIOASIS TECHNOLOGIES, INC. (CA) | 2021-11-25 | — | — | WO | claimed |
| US-20210113703-A1 | TREATMENT OF GAUCHER DISEASE | BIOASIS TECHNOLOGIES INC. (CA) | 2021-04-22 | — | — | US | claimed |
| EP-3796928-A2 | TREATMENT OF GAUCHER DISEASE | Bioasis Technologies Inc. (CA) | 2021-03-31 | — | — | EP | claimed |
| CN-112512558-A | Treatment of gaucher disease | 比奥阿赛斯技术有限公司 | 2021-03-16 | — | — | CN | claimed |
| EP-3419615-A1 | DIETARY PRODUCT DEVOID OF AT LEAST TWO NON ESSENTIAL AMINO ACIDS | Cancer Research Technology Ltd. (GB) | 2019-01-02 | — | — | EP | claimed |
| WO-2017144877-A1 | DIETARY PRODUCT DEVOID OF AT LEAST TWO NON ESSENTIAL AMINO ACIDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-08-31 | — | — | WO | claimed |
| EP-1399139-B1 | COMPOSITIONS BASED ON BRANCHED CHAIN AMINO ACIDS FOR IMPROVING THE MYOCARDIAL VENTRICULAR FUNCTION IN PATIENTS SUFFERING FROM DIABETES | PROFESSIONAL DIETETICS SRL (IT) | 2014-10-15 | — | — | EP | claimed |
| EP-1292615-B1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH CORP (US) | 2006-10-25 | — | — | EP | claimed |
| US-6664066-B2 | Mutant measles virus V protein; gene expression and engineering | WYETH HOLDINGS CORPORATION | 2003-12-16 | — | — | US | claimed |
| US-20030206925-A1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH HOLDINGS CORPORATION | 2003-11-06 | — | — | US | claimed |
| EP-4326284-A1 | INJECTABLE HYALURONIC ACID FORMULATIONS FOR USE IN INTRAARTICULAR, INTRADERMAL AND OPHTHALMIC APPLICATIONS | VSY Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi (TR) | 2024-02-28 | — | — | EP | disclosed |
| EP-4251209-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-5811293-A | CULTURE PRODUCT AS CHEMICAL INTERMEDIATE FOR ANTI-OBESITY AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| US-5629200-A | MICROORGANISM | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| EP-0654534-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-24 | — | — | EP | disclosed |